Serine Supplements Boost T Cell Attack on Tumors in Preclinical Models

Serine, an amino acid long targeted for restriction in cancer therapy because tumor cells rely on it to proliferate, may work better as a supplement than as a dietary cut. A study published in Nature Communications reports that in multiple preclinical models, adding serine therapeutically suppressed tumor growth and metastasis while simultaneously increasing the proliferation and effector functions of CD8+ T cells, the immune cells that kill cancer cells.

The finding hinges on a metabolic tug-of-war inside the tumor microenvironment. According to the researchers, activated T cells release the inflammatory signal interferon-gamma, which triggers a STAT1-dependent program in tumor cells. That program ramps up production of SLC1A4, a serine transporter on the tumor cell surface. The tumor cells then consume extracellular serine so aggressively that infiltrating CD8+ T cells are starved of it, undermining their anti-tumor activity.

When the team genetically deleted SLC1A4 from tumor cells, this metabolic hijack was reversed. Serine availability within the tumor microenvironment was restored, and anti-tumor immunity was markedly enhanced, the authors report. Dietary serine supplementation reproduced the immune-activating effects seen with SLC1A4 loss, suggesting a practical way to counter the transporter’s activity without genetic intervention.

The supplementation strategy also appeared to overcome resistance to PD-1 checkpoint blockade. In tumors that were refractory to this immunotherapy, serine supplementation produced durable disease control in the preclinical models, positioning the approach as a potential partner for existing checkpoint inhibitors.

The authors conclude that these data support serine supplementation, rather than restriction, as a readily translatable strategy to reinvigorate exhausted T cells and improve immunotherapy outcomes. Because serine restriction has been difficult to apply therapeutically despite its known ability to suppress tumor cell proliferation, the reversal of that logic is the study’s central surprise.

Important caveats apply. All findings come from preclinical models, and the paper was shared as an accepted manuscript that remains subject to further editorial revisions before the final version of record. Whether dietary serine supplementation can safely and effectively replicate these immune effects in human cancer patients has not yet been demonstrated, and clinical testing would be needed to establish dosing, safety and benefit in people.

Subject of Research: How tumor cells deplete serine to starve T cells and how supplementation reverses this in preclinical cancer models

Article Title: Serine supplementation reinvigorates anti-tumor immunity by counteracting tumor cell SLC1A4-induced T cell starvation

Article References: Koda, S., Wang, M., Chen, Y., Liu, Y., Putz, E. M., Deng, B., Zheng, S., Ju, X., Deng, X., Zheng, K., Li, X., Zhao, Y., Hu, J., & Yan, J. (2026). Serine supplementation reinvigorates anti-tumor immunity by counteracting tumor cell SLC1A4-induced T cell starvation. Nature Communications. https://doi.org/10.1038/s41467-026-78913-y

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78913-y

Keywords: serine, SLC1A4, CD8+ T cells, tumor microenvironment, immunotherapy, PD-1 blockade, interferon-gamma, STAT1, cancer metabolism, preclinical models, supplementation, reinvigorates